Previous 10 | Next 10 |
Medical technology company Viveve Medical ( NASDAQ: VIVE ) received a patent for the company's dual-energy technology by the Taiwan Intellectual Property Office. The Taiwan Patent No. I766557 further expands and strengthens VIVE's intellectual property portfolio in the...
ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright Global Investment Conference, May 23 - 26, 2022. Mr. Dur...
Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's i...
Viveve Medical, Inc. (VIVE) Q1 2022 Earnings Conference Call May 12, 2022 05:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Jim Robbins - Senior Vice President, Finance and Administration Scott Durbin - Chief Executive Officer Conference Call Partici...
Viveve Medical press release (NASDAQ:VIVE): Q1 GAAP EPS of -$0.67 beats by $0.01. Revenue of $1.64M (+13.1% Y/Y) beats by $0.03M. Increased the installed base of Viveve Systems to 895 systems worldwide. Cash and cash equivalents were $14.0 million as of March 31, 2022, compared to $19.2 ...
Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / May 12, 2022 / Viveve Medical, Inc. (NASDA...
ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2022 financial results and provide a corporate update after the close of the U.S. financial...
Viveve Medical Inc. (VIVE) Q4 2021 Earnings Conference Call March 17, 2022 5:00 PM ET Company Participants Jeannie Swindle - Senior Director of Corporate Communications Scott Durbin - CEO and Director Jim Robbins - SVP, Finance and Administration Presentation Operator Good afternoon, and welc...
Viveve Medical press release (NASDAQ:VIVE): FY GAAP EPS of -$2.65 misses by $0.13. Revenue of $6.43M (+17.3% Y/Y) beats by $0.01M. Shares -1.99%. For further details see: Viveve Medical GAAP EPS of -$2.65 misses by $0.13, revenue of $6.43M beats by $0.01M
Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment follow-up visits underway PURSUIT top-line results anticipated at end of 20...
News, Short Squeeze, Breakout and More Instantly...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-12-31 MedAvail Holdings Inc. (MDVL) is expected to report for Q3 2023 Nobility Homes, Inc. (NOBH) is expected to report for quarter end 2023-10-31 Walgreens Boots Alliance Inc. (WBA) is expected to report $0.66 for Q1 ...
Disco Corporation ADR (DSCSY) is expected to report for Q2 2024 Sonic Foundry Inc. (SOFO) is expected to report for quarter end 2023-09-30 Sono Group N.V. (SEVCQ) is expected to report for quarter end 2023-09-30 Minim Inc (MINM) is expected to report for Q3 2023 Enel Spa ADR (ENLA...
Enel Spa ADR (ENLAY) is expected to report for Q3 2023 LEG Immobilien SE Registered Shares (LEGIF) is expected to report for Q3 2023 G. Willi-Food International Ltd. (WILC) is expected to report for Q3 2023 Worthington Steel Inc. (WS) is expected to report $0.15 for Q2 2024 Sonic ...